HC Wainwright & Co. Initiates Coverage On Upstream Bio with Buy Rating, Announces Price Target of $36

Benzinga Newsdesk www.benzinga.com Neutral 66.2%

Neg 0% Neu 66.2% Pos 0%

HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Upstream Bio (NASDAQ:UPB) with a Buy rating and announces Price Target of $36.